
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, DC 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported)
August 1, 2013

Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction
of incorporation)

001-34899
(Commission
File Number)

16-1590339
(IRS Employer
Identification No.)

1380 Willow Road
Menlo Park, California 94025
(Address of principal executive offices, including zip code)

(650) 521-8000
(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

On August 1, 2013, Pacific Biosciences of California, Inc. announced its financial results for the quarter ended June 30, 2013. A copy of the press release containing the announcement is included as Exhibit 99.1 and is incorporated herein by reference.

This information, as well as Exhibit 99.1, is intended to be furnished under Item 2.02 of Form 8-K, "Results of Operations and Financial Condition" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.

(d) Exhibits.

99.1 Press Release dated August 1, 2013 titled "Pacific Biosciences of California, Inc. Announces Second Quarter 2013 Financial Results" (furnished and not filed herewith solely pursuant to Item 2.02).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Pacific Biosciences of California, Inc.

By: _____ /s/ Brian B. Dow
Brian B. Dow
Vice President and Principal Accounting Officer

Date: August 1, 2013

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated August 1, 2013 titled "Pacific Biosciences of California Announces Second Quarter 2013 Financial Results" (furnished and not filed herewith solely pursuant to Item 2.02).

**Pacific Biosciences of California, Inc. Announces
Second Quarter 2013 Financial Results**

Menlo Park, Calif. – August 1, 2013 – Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for the second quarter ended June 30, 2013.

Revenue for the second quarter of 2013 totaled \$6.0 million, compared to \$5.6 million for the first quarter of 2013. Revenue reflected the installation of three PacBio RS II systems, compared to three systems in the first quarter of 2013, SMRT® Cell and reagent consumables and instrument service contracts. Net loss for the quarter was \$20.5 million, compared to \$21.1 million during the first quarter of 2013.

Gross profit for the second quarter of 2013 was \$1.1 million, resulting in a gross margin of 18%, compared to gross profit of \$0.9 million and a resulting gross margin of 17% for the first quarter of 2013.

Operating expenses totaled \$21.1 million for the second quarter of 2013, compared to \$21.5 million for the first quarter of 2013. Operating expenses in the second quarter of 2013 included \$2.3 million of non-cash stock-based compensation compared to \$2.6 million in non-cash stock-based compensation in the first quarter of 2013.

Cash and investments at June 30, 2013 totaled \$107.0 million compared to \$112.3 million at March 31, 2013. The decrease in cash and investments during the period reflects cash use of \$16.6 million partially offset by \$11.3 million of cash received from the sale of stock.

The Company added seven PacBio RS II instrument bookings during the quarter and ended the quarter with 10 instruments in backlog.

Quarterly Conference Call Information

Management will host a quarterly conference call to discuss its second quarter 2013 results today at 4:30pm Eastern Time / 1:30pm Pacific Time. Investors may listen to the call by dialing 1.888.366.7247, or if outside the U.S., by dialing +1.707.287.9330. The call will be webcast live and will be available for replay at Pacific Biosciences' website at <http://investor.pacificbiosciences.com/>.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (NASDAQ: PACB) offers the PacBio® RS II Sequencing System to help scientists solve genetically complex problems. Based on its novel Single Molecule, Real-Time (SMRT®) Sequencing technology, the company's products enable: targeted sequencing to more comprehensively characterize genetic variations; *de novo* genome assembly to more fully identify, annotate and decipher genomic structures; and DNA base modification identification to help characterize epigenetic regulation and DNA damage. By providing access to information that was previously inaccessible, Pacific Biosciences enables scientists to increase their understanding of biological systems.

Forward-Looking Statements

This press release contains forward-looking statements relating to the Company's operations and operating results, including statements relating to the Company's backlog and future revenue implied by such backlog. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond the Company's control and that could materially affect actual results. Factors that could materially affect actual results can be found in the Company's filings with the Securities and Exchange Commission, including the most recently filed Quarterly Report on Form 10-Q, and include those listed under the caption "Risk Factors." The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

Contact:

Trevin Rard
650.521.8450
ir@pacificbiosciences.com

Pacific Biosciences of California, Inc.
Unaudited Consolidated Statement of Operations and Comprehensive Loss
(amounts in thousands, except per share amounts)

	Quarters Ended		
	June 30, 2013	March 31, 2013	June 30, 2012
Revenue:			
Product revenue	\$ 4,601	\$ 3,833	\$ 5,827
Service and other revenue	1,447	1,475	1,284
Grant revenue	—	270	180
Total revenue	<u>6,048</u>	<u>5,578</u>	<u>7,291</u>
Cost of revenue:			
Cost of product revenue	3,322	3,200	5,382
Cost of service and other revenue	1,667	1,448	1,634
Total cost of revenue	<u>4,989</u>	<u>4,648</u>	<u>7,016</u>
Gross profit (loss)	<u>1,059</u>	<u>930</u>	<u>275</u>
Operating expense:			
Research and development	11,682	11,983	11,272
Sales, general and administrative	9,374	9,554	11,558
Total operating expense	<u>21,056</u>	<u>21,537</u>	<u>22,830</u>
Operating loss	(19,997)	(20,607)	(22,555)
Interest Expense	(673)	(426)	(69)
Other income (expense), net	199	(71)	137
Net loss	<u>\$(20,471)</u>	<u>\$(21,104)</u>	<u>\$(22,487)</u>
Basic and diluted net loss per share	<u>\$ (0.33)</u>	<u>\$ (0.37)</u>	<u>\$ (0.40)</u>
Shares used in computing basic and diluted net loss per share	<u>61,922</u>	<u>57,372</u>	<u>55,658</u>
Comprehensive loss	<u>\$(20,484)</u>	<u>\$(21,123)</u>	<u>\$(22,547)</u>

Pacific Biosciences of California, Inc.
Unaudited Consolidated Statement of Operations and Comprehensive Income
(amounts in thousands, except per share amounts)

	Year to Date	
	June 30, 2013	June 30, 2012
Revenue:		
Product revenue	\$ 8,434	\$ 14,542
Service and other revenue	2,922	2,337
Grant revenue	270	450
Total revenue	<u>11,626</u>	<u>17,329</u>
Cost of revenue:		
Cost of product revenue	6,522	13,989
Cost of service and other revenue	3,115	3,217
Total cost of revenue	<u>9,637</u>	<u>17,206</u>
Gross profit	<u>1,989</u>	<u>123</u>
Operating expense:		
Research and development	23,665	23,345
Sales, general and administrative	18,928	26,843
Total operating expense	<u>42,593</u>	<u>50,188</u>
Operating loss	(40,604)	(50,065)
Interest expense	(1,098)	(139)
Other income (expense), net	127	137
Net loss	<u>\$ (41,575)</u>	<u>\$ (50,067)</u>
Basic and diluted net loss per share	<u>\$ (0.70)</u>	<u>\$ (0.90)</u>
Shares used in computing basic and diluted net loss per share	<u>59,660</u>	<u>55,433</u>
Comprehensive loss	<u>\$ (41,607)</u>	<u>\$ (50,049)</u>

Pacific Biosciences of California, Inc.
Unaudited Condensed Consolidated Balance Sheets
(amounts in thousands)

	June 30, 2013 <u>(unaudited)</u>	March 31, 2013 <u>(unaudited)</u>	December 31, 2012 (1) <u></u>
Assets			
Cash and investments	\$ 106,968	\$ 112,305	\$ 100,580
Accounts receivable	4,104	2,009	2,822
Inventory	10,283	10,597	9,592
Prepaid and other current assets	759	1,570	2,006
Total current assets	122,114	126,481	115,000
Property and equipment	11,655	12,779	14,329
Other assets	508	514	354
Total Assets	\$ 134,277	\$ 139,774	\$ 129,683
Liabilities and Stockholders' Equity			
Accounts payable	\$ 2,605	\$ 3,011	\$ 2,988
Deferred revenue	3,347	2,961	3,378
Accrued and other current liabilities	9,141	7,607	8,377
Total current liabilities	15,093	13,579	14,743
Facility financing and other non-current liabilities	4,885	5,254	5,558
Financing derivative	894	999	—
Notes Payable	13,007	12,851	—
Stockholders' equity	100,398	107,091	109,382
Total Liabilities and Stockholders' Equity	\$ 134,277	\$ 139,774	\$ 129,683

Note 1: The condensed consolidated balance sheet at December 31, 2012 has been derived from the audited consolidated financial statements at that date included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2012.